Medicine for local soaking type targeted treatment of meniscus injury through administration in knuckle articular cavity

A technology of targeted therapy and internal administration, which is applied in drug combinations, antipyretics, pharmaceutical formulas, etc., can solve problems such as joint instability, unsatisfactory cure rate and effective rate, and large trauma, and achieve reliable curative effect, The effect of treatment of meniscal injury

Inactive Publication Date: 2017-12-19
袁明远
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the treatment methods commonly used in China are surgical extirpation or partial meniscus resection or repair under direct vision with arthroscopy, which has the disadvantages of large trauma, unsatisfactory cure rate and effective rate, and it may be compli

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0021] In view of this, the applicant innovatively applied for an invention patent: a local soaking type targeted treatment of meniscus injury drug administered into the knee joint cavity, characterized in that the drug is composed of the following composition ratio: polymer hyaluronic acid Sodium bicarbonate 25mg×2 sticks, 2ml / stick;

[0022] Lincomycin 0.6g×2 sticks, 5ml / stick;

[0023] Dexamethasone 5mg×2 sticks; 1ml / stick;

[0024] 0.9% normal saline 10ml x 1 bottle.

[0025] In a preferred but non-limiting embodiment of the present invention, the above-mentioned local immersion-type targeted treatment of meniscus injury drug for intracavity administration of the knee joint includes a non-ionic iohexol contrast agent with a concentration of 300 of batch number H20053800, Usually 5-10ml each time.

[0026] In a preferred but non-limiting embodiment of the present invention, the above-mentioned drug for local soaking targeted treatment of meniscus injury in the knee join...

Embodiment approach 2

[0028] Embodiment 2: It is basically the same as Embodiment 1, the main difference is that the dosage ratios of various drugs are different, which will not be described in detail here, but those skilled in the art should understand that even fine-tuning of dosage ratios is based on Reasonable fluctuations in specific circumstances do not affect the substantive content of the patent of the present invention.

[0029] In summary, the present invention provides a knee joint intracavity drug for local immersion targeted treatment of meniscus injury, mainly composed of high molecular weight sodium hyaluronate, lincomycin, dexamethasone, water and other drugs Composed according to a certain proportion of ingredients, the drug can be organically combined with a variety of meniscus diagnosis and treatment methods to achieve simple, safe, practical and efficient, and reliable curative effect, and can effectively treat meniscus injuries.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention especially relates to a medicine for local soaking type targeted treatment of meniscus injury through administration in knuckle articular cavity, belonging to the field of medical technology. The medicine comprises the following components: two ampoules of high-molecular sodium hyaluronate, wherein each ampoule has a volume of 2 ml and contains 25 mg of high-molecular sodium hyaluronate; two ampoules of lincomycin, wherein each ampoule has a volume of 5 ml and contains 0.6 g of lincomycin; two ampoules of dexamethasone, wherein each ampoule has a volume of 1 ml and contains 5 mg of dexamethasone; and one ampoule of normal saline, wherein the ampoule has a volume of 10 ml. The medicine provided by the invention is mainly prepared from high-molecular sodium hyaluronate, lincomycin, dexamethasone, normal saline and other drugs according to or partially according to certain composition and dosage; cooperatively used drugs are a non-ionic iodine contrast agent solution and a lidocaine local anesthetic; and the medicine can be organically combined with a variety of meniscus diagnosis and treatment means, is simple, safe, practical and efficient, has reliable curative effect and can effectively treat meniscus injury.

Description

technical field [0001] The invention relates to a preparation of medicine for treating meniscus injury of knee joint. Various medicines are mixed together according to certain dosages and uses, so as to obtain a new function of treating meniscus injury. The main components of the new drug include high molecular weight sodium hyaluronate, dexamethasone, and lincomycin, and the auxiliary components are physiological saline, non-ionic iodine solution contrast medium, and lidocaine anesthetic. Various drug ingredients have different functions and effects in the treatment of meniscus injury, and have obtained new functions of operation synergy and improvement of meniscus treatment effect. Background technique [0002] At present, the diagnosis of knee meniscus injury mainly relies on clinical examination, magnetic resonance imaging and arthroscopy. The cost of inspection is higher, and the inspection is more traumatic. The treatment plan generally adopts invasive operations suc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/728A61K31/7056A61K31/573A61K31/167A61K49/04A61P19/02A61P29/00A61P23/02
Inventor 袁明远龚磊
Owner 袁明远
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap